Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CRXL, XRAY, ENDP – Featured Stocks at NASDAQ Healthcare Sector by CRWEFinance.com


Crucell N.V. (ADR) (NASDAQ:CRXL) decreased 1.66% to close at $33.10. CRXL traded 2.24 million shares for the day and its earning per share remained $0.74. Crucell N.V. (Crucell) is a biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases. Crucell product candidates include flu-mAb, an antibody product effective against a range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination, all produced on its PER.C6 human cell-line technology. The Company focuses on the paediatric, travel and endemic, and respiratory markets.

DENTSPLY International Inc. (NASDAQ:XRAY) decreased 5.49% to close at $31.34. XRAY traded 3.34 million shares for the day and its earning per share remained $1.85. DENTSPLY International Inc (DENTSPLY) is a designer, developer, manufacturer and marketer of a range of products for the dental market. The Company conducts its business through four operating segments, all of which are primarily engaged in the design, manufacture and distribution of dental products in three principal categories: dental consumables, dental laboratory products and dental specialty products. The Company conducts its business in over 120 foreign countries, principally through its foreign subsidiaries.

Endo Pharmaceuticals (NASDAQ:ENDP) decreased 1.08% to close at $36.67. ENDP traded 2.10 million shares for the day and its earning per share remained $2.63. Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company in pain management. The Company is engaged in the research, development, manufacturing, marketing and sales of branded and generic pharmaceutical products used primarily to treat and manage pain, overactive bladder, prostate and bladder cancer and central precocious puberty. During the year ended December 31, 2009, the branded products comprised approximately 91% of the Company's net sales. In March 2009, Endo Pharmaceuticals Holdings Inc. completed the acquisition of Indevus Pharmaceuticals, Inc.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.



Disclosure: No positions